ischemic%20stroke
ISCHEMIC STROKE
Ischemic stroke occurs when a blood vessel supplying the brain is obstructed.
Consider stroke in any patient presenting with sudden focal neurological deficit or any alteration in level of consciousness.
Rapid evaluation is essential for sure of time-sensitive treatments.
Determine if patient's symptoms are due to stroke and exclude stroke mimics (eg migraine, hypertensive encephalopathy, hypoglycemia, seizures or post-ictal paresis); identify other conditions requiring immediate intervention and determine the potential causes of stroke.

Diagnosis

  • Determine if patient’s symptoms are due to stroke, identify other conditions requiring immediate intervention and determine the potential causes of stroke

History

  • Time of symptom onset is the single most important piece of historical information
    • Stroke onset defined as the last time patient was symptom-free
  • Obtain circumstances around the development of symptoms and features that may point to other potential causes of symptoms
  • Identify risk factors for arteriosclerosis and cardiac disease; medications, conditions that may predispose to bleeding complications; history of drug abuse, infection, migraine, seizure, trauma, oral contraceptive use or pregnancy

Physical Examination

  • Complete physical examination including vital signs, oxygen saturation and body temperature
  • Brief but thorough neurologic exam

Screening

Clinical Stroke Score

  • National Institute of Health (NIH) Stroke Scale
    • Helps quantify the degree or severity of neurological deficit and may identify possible location of lesion/occlusion
    • Facilitates communication between healthcare professionals and may provide prognostic information
    • May identify patients eligible for interventions and potential risk for complications

Laboratory Tests

Routine Laboratory Tests

  • Blood glucose, complete blood count (CBC) with platelet count, renal function tests, serum electrolytes, prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), D-dimer, fibrinogen
  • Cardiac biomarkers may be done to confirm or rule out acute coronary syndrome if needed

Perform the following tests, if required:

  • Toxicology screen, blood alcohol level
  • Arterial blood gas (if hypoxia is suspected)
  • Liver function tests
  • Pregnancy test
  • Chest radiograph (if lung disease is suspected)
  • Lumbar puncture (if subarachnoid hemorrhage is suspected and computed tomography (CT) is negative for blood)
  • Electroencephalography (EEG), if seizures are suspected

Imaging

  • Non-contrast Cranial Computed Tomography (CT)
    • Recommended to differentiate ischemic from hemorrhagic stroke or other structural brain lesions that may mimic stroke
    • A computed tomography scan may be normal within the 1st 24 hours of ischemia but will show hemorrhages from onset of stroke
    • Mandatory before initiating any specific therapy to treat acute ischemic stroke
    • Alberta Stroke Program Early Computed Tomography Score (ASPECTS) helps in the detection of early ischemic changes and should be evaluated in patients who are candidates for intravenous thrombolysis
  • Magnetic resonance imaging (MRI) of the brain
    • Magnetic resonance imaging is more sensitive and specific for diagnosis of ischemic stroke and determination of the extent of reversible or irreversible cerebral ischemia especially for stroke within 3-8 hours
    • Important in patients with unusual presentations, stroke varieties, or in whom stroke mimics are suspected but not clarified on computed tomography
  • Cranial Magnetic Resonance Imaging with Diffusion-Weighted Imaging (DWI)
    • Highly sensitive in detecting early cerebral ischemic changes in acute stroke patients
  • Vascular imaging
    • Computed tomography and magnetic resonance angiography, transcranial Doppler ultrasonography, carotid duplex sonography and catheter angiography have been used to detect intracranial or extracranial vessel abnormalities

Evaluation

Intravenous recombinant tissue plasminogen activator (rt-PA) should only be administered under the following conditions:

  • Physician and staff with expertise in acute stroke management, in delivering thrombolysis and in monitoring for complications
  • Immediate access to high-resolution imaging (eg noncontrast CT scan) facilities which are available 24 hours/day and staff trained and experienced in interpreting the results
  • Facility has the means to treat potential complications (eg intracerebral hemorrhage)
  • Intravenous rt-PA is given only to patients satisfying specific inclusion and exclusion criteria

Patient Inclusion Criteria

  • Ischemic stroke by clinical assessment confirmed through cranial computed tomography (CT) and shows no signs of hemorrhage
  • Patient must be ≥18 years of age
  • Initiation of treatment with rt-PA is within 3 hours after symptom onset; may extend time window up to 4.5 hours after symptom onset in selected patients

Patient Exclusion Criteria

Clinical Contraindications

  • Onset of stroke >3 hours prior to planned start of treatment
  • Neurologic deficit is minor or spontaneously and rapidly improving
  • Symptoms of stroke suggestive of subarachnoid hemorrhage, regardless of a computed tomography result
  • Hypertension: Systolic blood pressure (SBP) >185 mmHg and diastolic blood pressure (DBP) >110 mmHg on repeated measurements or if aggressive treatment is required to lower blood pressure
  • In the setting of middle cerebral artery (MCA) stroke, an obtunded or comatose state may be a relative contraindication
  • Signs of active bleeding or acute trauma (ie fracture) on examination
  • Seizure at stroke onset

History Contraindications

  • Major surgery (eg recent intracranial or spinal surgery) or serious trauma within the last 2 weeks
  • History of intracranial hemorrhage
  • Prior stroke or serious head injury in the preceding 3 months
  • Gastrointestinal or urinary tract hemorrhage within the preceding 14-21 days
  • Arterial puncture at a noncompressible site within the preceding 7 days or lumbar puncture within the last 3 days
  • Untreated cerebral aneurysm, arteriovenous malformation (AVM) or brain tumor
  • Clinical presentation suggestive of acute myocardial infarction (MI) or post-myocardial infarction pericarditis
  • Patient is taking oral anticoagulants and with INR >1.7 or prothrombin time >15 seconds
  • Patient has received heparin within the last 48 hours and has an elevated activated partial thromboplastin time greater than the upper limit of normal
  • Patient has received low molecular weight heparin within the last 24 hours
  • Pregnancy or possible pregnancy
  • Known hereditary or acquired hemorrhagic diathesis or unsupported coagulation factor deficiency

Laboratory Contraindications

  • Glucose <50 mg/dL or >400 mg/dL (<2.7 mmol/L or >22.2 mmol/L)
  • Platelet count <100,000 mm3
  • INR >1.7 and elevated activated partial thromboplastin time
  • Positive pregnancy test

Radiology Contraindications

  • Intracranial hemorrhage
  • Large area of low attenuation consistent with an infarcted brain (time of symptom onset may have been earlier)
  • Intracranial tumor, aneurysm, arteriovenous malformation or other space-occupying lesion

Additional Criteria (for patients who can be treated 3 to 4.5 hours after symptom onset)

Inclusion Criteria

  • Diagnosis of ischemic stroke causing measurable neurologic deficit
  • Onset of symptoms <3 hours prior to initiation of treatment

Relative Exclusion Criteria

  • Patients >80 years of age
  • Taking oral anticoagulants, regardless of INR level
    • May be re-evaluated if lab tests (eg activated partial thromboplastin time, INR, platelet count) are normal or if last dose of oral anticoagulant was taken >48 hours ago in patients with normal renal function
  • Severe stroke (National Institutes of Health Stroke Scale Score >25) or radiological evidence of infarction involving >1/3 of the middle cerebral artery territory
  • Combined prior history of stroke and diabetes
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
4 days ago
Higher circulating levels of docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA) appear to be protective against incident atherothrombotic and cardioembolic strokes, respectively, according to a recent study.
Roshini Claire Anthony, 6 days ago

The prevalence of resistant hypertension may be lower than expected, particularly once pseudo-resistant hypertension due to treatment nonadherence is taken into account, according to a presentation at the recent APCH 2017.

Pank Jit Sin, 07 Jan 2015

Cardiovascular diseases (CVD) have been the main cause of death in the Malaysian population since 2007. This trend has continued, with the number of people dying from CVD-related causes increasing year on year. 

Tristan Manalac, 5 days ago
Administration of a long-acting medication at the time that is most suitable for maximum patient compliance is the best approach in controlling blood pressure, said Dr. Trefor Morgan at the recently concluded 13th Asian-Pacific Congress of Hypertension (APCH 2017), held at the Suntec Singapore Convention and Exhibition Centre.